2022•Value in HealthOpen access

EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study

Massimo Filippi, Luigi Maria Edoardo Grimaldi, A Conte, Rocco Totaro, MR Valente, S. Malucchi, Franco Granella, Cinzia Cordioli, Vincenzo Brescia Morra, D Perini, L Santoni

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Natalizumab, Multiple sclerosis, Relapsing remitting, Medicine, Intensive care medicine, Immunology

Back to paper search Browse research topics Original source

EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study — Research Paper | ScholarLens